InvestLog
KALA KALA BIO, Inc. logo

KALA KALA BIO, Inc.

Healthcare
$2.43-6.54%ClosedMarket Cap: $53.3M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.84

P/S

0.00

EV/EBITDA

-1.81

DCF Value

$0.81

FCF Yield

-48.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-1335.6%

ROA

-159.6%

ROIC

-281.5%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-1.6M$—
Q4 null$0.00$686.0K$—
FY null$0.00$-27.0M$—
Q3 null$0.00$-7.6M$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$18.25

Target (Median)

$18.25

Target Range

$1.50 - $35.00

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Neutral
2025-09-29
HC Wainwright & Co.Buy
2025-09-17
OppenheimerOutperform
2025-09-11

Trading Activity

Insider Trades

View All
Purdy Brendan P.director:
SellMon Feb 09
Posen Hillel D.director:
SellMon Feb 09
Minkowitz Avrahamdirector, officer: Chief Executive Officer
SellMon Feb 09
Colman Yonatan C.director:
SellMon Feb 09
Berger Chaim D.director:
SellMon Feb 09

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

-2.24

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Peers

ABP logoABPAIM logoAIMCANF logoCANFENSC logoENSCIBO logoIBOKTTA logoKTTAOGEN logoOGENSNGX logoSNGXVYNE logoVYNEXTLB logoXTLB